Follicular Lymphoma, Grade 2
5 clinical trials · Condition
◉ Watch Follicular Lymphoma, Grade 2
| Record | Firm | Date |
|---|---|---|
| Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma (NCT03919175) | Massachusetts General Hospital | 2019-09-01 |
| Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy (NCT02966730) | Memorial Sloan Kettering Cancer Center | 2016-11-01 |
| "MIRO" Molecularly Oriented Immuno-radio-therapy (NCT02710643) | Fondazione Italiana Linfomi - ETS | 2014-10-01 |
Track Follicular Lymphoma, Grade 2 automatically
Every clearance here is in the API, with alerts when new ones post.